Cytokinetics Incorporated Common Stock (CYTK)
Stock · NASDAQ · Health Care
$61.97as of 10/16/2026
Price chart
Active signals
CYTK Signal Track Record
How signals performed across all stocks →What CYTK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -2.4% | 32% | September 8, 2026 |
| Bollinger Band Breakdown | 24 | +0.4% | 54% | August 28, 2026 |
| Bollinger Band Breakout | 22 | -7.1% | 27% | June 29, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -0.9% | 45% | September 15, 2026 |
| Any 20-session window (baseline) | -1.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 673
- Website
- cytokinetics.com/
Fundamentals
- 1-day range
- $63.81$65.57
- Market cap
- $10.13B
- P/E (trailing)
- —
- P/E (forward)
- -14.38
- EPS (trailing)
- $-7.22
- Dividend yield
- —
- Beta
- 0.42
- Avg. volume
- 1.97M
How Cytokinetics Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
20 analyst ratings
Cytokinetics Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
- SMMTSummit Therapeutics Inc. Common Stock$14.63▼ 4.81%Market cap $10.80BP/E —$12.07$29.23
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
- PTGXProtagonist Therapeutics Inc. Common Stock$128.75▼ 5.71%Market cap $9.40BP/E 107.21$73.08$160.81
- SYRESpyre Therapeutics Inc. Common Stock$79.9▼ 0.25%Market cap $9.12BP/E —$21.01$110.18
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $14.63 | ▼ 4.81% | $12.07$29.23 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | 107.21 | $128.75 | ▼ 5.71% | $73.08$160.81 |
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $79.9 | ▼ 0.25% | $21.01$110.18 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Cytokinetics with Outperform Ratingbenzinga · 10/16/2026
- RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113Benzinga · 10/8/2026
- Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Yahoo · 10/2/2026
- Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026Yahoo · 10/2/2026
- Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And MoreSeekingAlpha · 9/30/2026
- Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic CardiomyopathyYahoo · 9/30/2026
- Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyBenzinga · 9/30/2026
- Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts ApproachBenzinga · 9/25/2026
- Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein ConferenceYahoo · 9/25/2026
Insider Activity
Insider Actions →- Fady Ibraham Malik · October 6, 2026 · Option Exercise3.5K @ $7.8
- Fady Ibraham Malik · October 6, 2026 · Sale3.5K @ $61.38
- Robert I. Blum · September 28, 2026 · Option Exercise7.5K @ $10.6
- Robert I. Blum · September 28, 2026 · Sale7.5K @ $65.46
- Fady Ibraham Malik · September 22, 2026 · Option Exercise3.5K @ $7.8
- Fady Ibraham Malik · September 22, 2026 · Sale3.5K @ $68.29
- Robert E. Landry · September 15, 2026 · Sale1.0K @ $72.13
- Robert I. Blum · September 15, 2026 · Sale97.9K @ $69.33
- Robert I. Blum · September 14, 2026 · Option Exercise7.5K @ $10.6
- Robert I. Blum · September 14, 2026 · Gift97.9K
- Robert I. Blum · September 14, 2026 · Gift1.4K
- Robert I. Blum · September 14, 2026 · Sale7.5K @ $73.44
- Robert E. Landry · September 11, 2026 · Sale1.0K @ $74.66
- Fady Ibraham Malik · September 8, 2026 · Option Exercise3.5K @ $7.8
- Fady Ibraham Malik · September 8, 2026 · Sale3.5K @ $75.46
Institutional Ownership
March 31, 2026
- Total shares held
- 148.78M
- Total value held
- $8.46B
- Institutional holders
- 438
- Unknown17.52M
- Unknown16.55M
- Unknown10.72M
- Unknown8.01M
- Unknown5.75M
- Unknown5.49M
- Unknown3.33M
- Unknown3.22M
- Unknown3.13M
- Unknown2.72M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cytokinetics Launches ASPEN-HCM Real-World Study
Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.
Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.